Quintiles today announced a comprehensive suite of biomarker assays to help bio pharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.
Quintiles Announces Suite of PI3K Biomarker Assays to Advance Oncology Therapies Targeting this Cancer Pathway
Power3 Medical to Publish Medical Breakthrough Documented During Clinical Trials of Power3 Medical’s Flag Ship NuroPro(R) Diagnostic
Power3 Medical Products, Inc. (OTCBB: PWRM – News) announced today that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announced today that the Van Andel Research Institute (VARI), part of the Van Andel Institute, will utilize the Aushon 2470 Arrayer technology in its Laboratory of Cancer Immunodiagnostics to advance research efforts focusing on developing novel protein analysis methods to identify and study protein abnormalities in the blood of cancer patients. The goal of the research is to develop blood tests for the early detection or more accurate diagnosis of cancer.
Covance announced today that it has created a new Discovery & Translational Services group, which will integrate its discovery services, antibody products and immunology services, Biomarker Center of Excellence, and Genomics Laboratory. Leveraging its minority equity stake in Caprion Proteomics, Inc. and alliance with Rules-Based Medicine, Inc., Covance’s Discovery & Translational Services group will offer clients a depth and breadth of drug discovery and biomarker services that is unmatched in the CRO industry.
If a factory is where raw components are manufactured and assembled into commercial products, then why not take a similar approach to developing diagnostics to predict disease predisposition and response to drugs?
Duke University and the Laboratory Corporation of America have put their collective expertise together to create just such an enterprise, which they’ve dubbed the Biomarker Factory. The project, announced earlier this month, enjoins Duke University Medical Center’s expertise in biomarker discovery and LabCorp’s capacity to develop laboratory-developed tests from validated biomarkers.